ArticleMedicine2026
Exploring the potential targets and mechanisms of malachite green induced lung adenocarcinoma through network toxicology and molecular docking.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Malachite green (MG), a synthetic dye, has turned into a major risk to human health, because of its toxicity of teratogenic, genotoxic, carcinogenic, and immunosuppressive properties. And the result of ADMETLAB 2.0 platform prediction shows that MG is highly toxic to the respiratory system in our study. However, no study has conducted to verify and explain the association between MG and lung adenocarcinoma (LUAD). In the current investigation, a total of 34 candidate target genes that might be involved in MG-mediated modulation in LUAD were identified and screened through integrated machine learning algorithms, including LASSO regression and random forest analysis. Subsequent functional annotation revealed that these genes were predominantly enriched in biological processes associated with the cell cycle. Meanwhile, pathway analysis indicated that the majority of these genes were closely linked to the p53 signaling pathway. Furthermore, molecular docking simulation validated that MG could stably and specifically bind to TP53, CCNB1, and MAPK1 proteins. In summary, our results demonstrated that MG may participate in the tumorigenesis and progression of LUAD, mainly by regulating the cell cycle via the p53 and MAPK signaling pathways. Among these, TP53, CCNB1, and MAPK1 could act as crucial candidate targets in MG‑mediated LUAD development. These findings provide novel insights into the molecular mechanisms underlying the role of MG in LUAD, and lay a theoretical basis for the future prevention and targeted therapy of LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.